{"id":1700,"date":"2026-02-06T19:54:09","date_gmt":"2026-02-06T19:54:09","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/1700\/"},"modified":"2026-02-06T19:54:09","modified_gmt":"2026-02-06T19:54:09","slug":"whats-going-on-with-novo-nordisk-stock-on-friday-novo-nordisk-nysenvo","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/1700\/","title":{"rendered":"What’s Going On With Novo Nordisk Stock On Friday? – Novo Nordisk (NYSE:NVO)"},"content":{"rendered":"

Novo Nordisk A\/S (NYSE:<\/a>NVO<\/a>) is trading higher on Friday after falling for two consecutive days on lower-than-expected fiscal 2026 guidance<\/a> and compounding concerns.<\/p>\n

\u2022 Novo Nordisk stock is showing exceptional strength. What\u2019s behind NVO gains?<\/a><\/p>\n

On Tuesday, the company said it expects adjusted sales growth for 2026, which excludes revenue from the reversal of 340B provisions, to be -5% to -13% at constant exchange rates (CER)<\/a>.<\/p>\n

Hims and Hers said that eligible customers can access treatment plans that include Compounded Semaglutide Pills at a special introductory offer starting at just $49 for the first month<\/a>.<\/p>\n

Novo Nordisk issued a statement saying Hims & Hers will unlawfully mass-market an unapproved, inauthentic and untested knockoff semaglutide pill.<\/p>\n

\u201cThe action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety. Novo Nordisk will take legal and regulatory action\u2026\u201d This is another example of Hims & Hers\u2019 historic behaviour of duping the American public with knockoff GLP-1 products, and the FDA has previously warned them about their deceptive advertising of GLP-1 knockoffs.\u201d<\/p>\n

Novo Nordisk stock gained after the U.S. Food and Drug Administration (FDA) said to take action against illegal copycat drugs.<\/p>\n

In a social media post on Friday, the U.S. Food and Drug Administration commissioner Marty Makary said<\/a>, \u201cFDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products. The FDA cannot verify the quality, safety or effectiveness of non-approved drugs.\u201d<\/p>\n

Though the post did not mention or list any products or companies.<\/p>\n

NVO Price Action: Novo Nordisk stock is up 8.32% at $46.96 at the time of publication on Friday. The stock is trading 8.6% above its 52-week low, according to Benzinga Pro data<\/a>.<\/p>\n

Photo: Piotr Swat via Shutterstock<\/p>\n

Market News and Data brought to you by Benzinga APIs<\/a><\/p>\n

\u00a9 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n

To add Benzinga News as your preferred source on Google, click here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S (NYSE:NVO) is trading higher on Friday after falling for two consecutive days on lower-than-expected fiscal…\n","protected":false},"author":2,"featured_media":1701,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2085,2094,2091,2086,2089,2087,2090,2092,2088,2093,2084,272,352,2095,2096,2097,2098,2099,2100],"class_list":{"0":"post-1700","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-global","11":"tag-category-government","12":"tag-category-health-care","13":"tag-category-large-cap","14":"tag-category-legal","15":"tag-category-movers","16":"tag-category-news","17":"tag-category-trading-ideas","18":"tag-cms-wordpress","19":"tag-novo-nordisk","20":"tag-pageisbzpro-bz","21":"tag-symbol-hims","22":"tag-symbol-nvo","23":"tag-tag-fda","24":"tag-tag-wegovy","25":"tag-tag-weight-loss","26":"tag-tag-why-its-moving"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/1700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=1700"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/1700\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/1701"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=1700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=1700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=1700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}